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Patients With Atrial Fibrillation?Dr. de Boer brings up some important design con-
siderations regarding our analysis of the TREAT-AF
(Retrospective Evaluation and Assessment of Ther-
apies in AF) study (1). He correctly argues that there
can be misclassiﬁcation of digoxin exposure in our
design. Our observational study was designed as an
intention-to-treat analysis, comparing the strategies
of use and nonuse of digoxin as initial or early
therapy in patients with newly diagnosed atrial
ﬁbrillation (AF) (1). Although we found that 80% of
patients in the digoxin arm were still on therapy
at 1 year, there is a strong possibility of digoxin
exposure in the control arm after 90 days. How-
ever, we believe this would not represent “mis-
classiﬁcation” in an intention-to-treat design but
rather crossover of therapy. Generally, crossover
would bias toward the null and therefore would not
likely account for the observed difference in
outcomes.
Therapy crossover is common in management of
AF and complicates analysis and interpretation of
randomized trials. Crossover may be motivated by
observed and unobserved confounders, which can
further complicate analysis and may in part explain
the seemingly incongruent results of 2 secondary
analyses of digoxin using the same AFFIRM (AF
Follow-Up Investigation of Rhythm Management)
trial data set (2,3). Separating patients into exposed
and unexposed blocks of person-time without
adjusting for time-varying confounders could exag-
gerate treatment effect (or harm) (4). On the other
hand, contemporary approaches such as marginal
structural models that incorporate time-varying datacan bias toward the null from overadjustment or
model misspeciﬁcation (5).
For these reasons, we elected to study a new dis-
ease cohort using an intention-to-treat design that
evaluated digoxin as an initial treatment strategy.
Our decision to adjust for adherence rather than to
stratify was to account for variation in adherence in
the overall point estimate. We agree that further work
to explore the heterogeneity of treatment effects
across strata of adherence and time course of therapy
would be valuable and complementary.*Mintu P. Turakhia, MD, MAS
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and Paradoxical
Systemic Embolism
Can We Determine High-Risk Characteristics
by Echocardiography?We read with interest the review paper on paradoxi-
cal embolism by Windecker et al. (1). It was sug-
gested, on the basis of available evidence from
published reports, that device closure of patent
foramen ovale (PFO) should be considered in patients
with ﬁrst-time cryptogenic stroke, particularly in
those with high-risk criteria, such as presence of
an atrial septal aneurysm (ASA), large PFO, Eusta-
chian valve, or Chiari network. The viewpoints of
